These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17725208)

  • 21. Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate.
    Agarwal R
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1340-6. PubMed ID: 20448071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The treatment of anemia in chronic kidney disease: understandings in 2006.
    Levin A
    Curr Opin Nephrol Hypertens; 2007 May; 16(3):267-71. PubMed ID: 17420672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [What are the aims and targets of renal anemia therapy?].
    Eckardt KU
    Dtsch Med Wochenschr; 2007 Sep; 132(36):1837-41. PubMed ID: 17726657
    [No Abstract]   [Full Text] [Related]  

  • 25. Anemia of chronic kidney disease: CHOIR and the FDA.
    Singh AK
    Nat Clin Pract Nephrol; 2007 Aug; 3(8):406-7. PubMed ID: 17593919
    [No Abstract]   [Full Text] [Related]  

  • 26. Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment.
    Kliger AS; Fishbane S; Finkelstein FO
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):354-7. PubMed ID: 22266571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
    Nurko S; Spirko R; Law A; Dennis VW
    Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Renal anemia treatment and outcome of patients with chronic kidney disease].
    Kuragano T; Nakanishi T
    Nihon Jinzo Gakkai Shi; 2009; 51(7):852-6. PubMed ID: 19928557
    [No Abstract]   [Full Text] [Related]  

  • 29. Hemoglobin levels, cardiovascular disease, and left ventricular hypertrophy in patients with chronic kidney disease. Case study of the anemic patient.
    Butler KG
    Nephrol Nurs J; 2002 Apr; 29(2):189-92. PubMed ID: 11997954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?
    Singh AK
    Curr Opin Nephrol Hypertens; 2010 Sep; 19(5):420-4. PubMed ID: 20689425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [TREAT or not to treat: anemia in type 2 diabetes and chronic kidney disease at stages 3 and 4].
    Choukroun G; Renou M; Lecaque C; Jauréguy M
    Nephrol Ther; 2011 Feb; 7(1):2-9. PubMed ID: 21216683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypothesis versus association: the optimal hemoglobin target debate.
    Strippoli GF; Craig JC
    Am J Kidney Dis; 2005 Nov; 46(5):970-3. PubMed ID: 16253741
    [No Abstract]   [Full Text] [Related]  

  • 33. Debate: CON Position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed?
    Locatelli F; Del Vecchio L
    Am J Nephrol; 2010; 31(6):557-60; discussion 561-2. PubMed ID: 20501989
    [No Abstract]   [Full Text] [Related]  

  • 34. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
    Collins AJ; Brenner RM; Ofman JJ; Chi EM; Stuccio-White N; Krishnan M; Solid C; Ofsthun NJ; Lazarus JM
    Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An expert opinion on the current treatment of anemia in patients with kidney disease.
    Locatelli F; Del Vecchio L
    Expert Opin Pharmacother; 2012 Mar; 13(4):495-503. PubMed ID: 22296648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Editorial perspective. Should hemoglobin targets for anemic patients with chronic kidney disease be changed?
    Parfrey PS
    Am J Nephrol; 2010; 31(6):565-6. PubMed ID: 20501992
    [No Abstract]   [Full Text] [Related]  

  • 37. Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease.
    Mix TC; Brenner RM; Cooper ME; de Zeeuw D; Ivanovich P; Levey AS; McGill JB; McMurray JJ; Parfrey PS; Parving HH; Pereira BJ; Remuzzi G; Singh AK; Solomon SD; Stehman-Breen C; Toto RD; Pfeffer MA
    Am Heart J; 2005 Mar; 149(3):408-13. PubMed ID: 15864229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy.
    Foley RN; Curtis BM; Parfrey PS
    Clin J Am Soc Nephrol; 2008 Nov; 3(6):1669-75. PubMed ID: 18922988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Debate: PRO Position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed?
    Singh AK
    Am J Nephrol; 2010; 31(6):552-6; discussion 563-4. PubMed ID: 20501988
    [No Abstract]   [Full Text] [Related]  

  • 40. Cardiorenal anemia syndrome in chronic kidney disease.
    Tarng DC
    J Chin Med Assoc; 2007 Oct; 70(10):424-9. PubMed ID: 17962140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.